The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Clinical Diabetes
Volume 16 - 2025 |
doi: 10.3389/fendo.2025.1437858
Electrochemical Skin Conductance: A Tool for Risk Stratification and Early anticipation of Diabetic Foot Ulcers Authors
Provisionally accepted
Jean-François Gautier 1,2* Jean-Pierre Riveline 1,3*
Louis POTIER 3,4
Olivier Bourron 5 Lyse Bordier 6*
Benjamin Vittrant 7 Ronan Roussel 4* Bernard Bauduceau 6*- 1 Diabetology and Endocrinology Department, Lariboisière Hospital, Paris, France, Paris, France
- 2 Institut Necker-Enfants Malades, Université Paris Cité, INSERM UMR-S1151, CNRS, Paris, France, Paris, France
- 3 INSERM U1151 Institut Necker Enfants Malades, Paris, Île-de-France, France
- 4 Diabetology – Endocrinology Department, Bichat-Claude-Bernard Hospital, AP-HP, Paris, France, Paris, France
- 5 Diabetology – Endocrinology and Metabolism Department, La Pitié-Salpêtrière Hospital, Paris, France, Paris, France
- 6 Diabetology – Endocrinology and metabolism Department, Begin Hospital, saint-Mande, France, Paris, France
- 7 Withings, Issy-les-Moulineaux, France
Diabetic foot ulcers (DFUs) present a significant challenge in diabetes care, with high morbidity, mortality, and healthcare costs. This study introduces an innovative approach to DFU risk stratification using Electrochemical Skin Conductance (ESC) measurements from the Sudoscan device, which may offer improved patient outcomes over traditional clinical examinations. We assessed the association between ESC measures and DFU risk stratification scores in 2157 patients with diabetes from four French hospitals. Our analysis revealed a quantitative association between ESC and DFU grades, with the potential to provide greater granularity in early-stage DFUs. This research highlights the potential of ESC in transforming DFU management and advancing equitable healthcare delivery for patients with diabetes.
Keywords: diabete follow-up, diabetes foot ulcers, Electrical skin conductance, SUDOSCAN, Withings
Received: 31 May 2024; Accepted: 04 Feb 2025.
Copyright: © 2025 Gautier, Riveline, POTIER, Bourron, Bordier, Vittrant, Roussel and Bauduceau. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jean-François Gautier, Diabetology and Endocrinology Department, Lariboisière Hospital, Paris, France, Paris, France
Jean-Pierre Riveline, Diabetology and Endocrinology Department, Lariboisière Hospital, Paris, France, Paris, France
Lyse Bordier, Diabetology – Endocrinology and metabolism Department, Begin Hospital, saint-Mande, France, Paris, France
Ronan Roussel, Diabetology – Endocrinology Department, Bichat-Claude-Bernard Hospital, AP-HP, Paris, France, Paris, France
Bernard Bauduceau, Diabetology – Endocrinology and metabolism Department, Begin Hospital, saint-Mande, France, Paris, France
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.